Press Release

Morgan Lewis Advises Proteon Therapeutics in Combination with ArTara

September 24, 2019

BOSTON, September 24, 2019: Morgan Lewis advised Proteon Therapeutics Inc. in its reverse merger agreement with ArTara Therapeutics Inc. Under the agreement, a wholly owned subsidiary of Proteon will merge with ArTara in an all-stock transaction.

In conjunction with the merger agreement, Morgan Lewis represented Proteon in a PIPE financing, which saw a syndicate of healthcare-dedicated investors enter into a stock purchase agreement to invest $42.5 million in the combined company.

Proteon Therapeutics is a Massachusetts-based company developing novel pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. ArTara Therapeutics is a private clinical stage biopharmaceutical company developing treatments for rare and specialty diseases with unmet therapeutic needs.

Partner Julio Vega led the Morgan Lewis team with assistance from associates Tara McElhiney and Zachary Zemlin.

For more, read Proteon’s announcement.